EUVIMEDEUVIMED entdecken
Crossref

Drugs and bruxism: A study in the World Health Organization's pharmacovigilance database

Jean-Louis Montastruc iD

British Journal of Clinical Pharmacology · 2023-12 · 89 (12) · 3765-3768

DOI: 10.1111/bcp.15884 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 30.08.2023. Verfasst von Jean-Louis Montastruc. Beteiligte Einrichtung: Emeritus Professor of Medical and Clinical Pharmacology, Toulouse, France. Hauptthemen laut MEDLINE: Selective Serotonin Reuptake Inhibitors, Bruxism. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bruxism is a movement disorder of uncertain aetiology. Beside local peripheral and central psychological factors, drugs were suspected. Using the World Health Organization (WHO) global pharmacovigilance database, Vigibase®, we investigated through disproportionality analyses potential associations between exposure to drugs and bruxism reports. All reports of bruxism in adults between 01/01/2000 and 31/12/2022 were included. Results are expressed as reporting odds ratio (ROR). Among the 564 reports of bruxism, an association was found with eight antidepressants (first sertraline followed by escitalopram, venlafaxine, vortioxetine, citalopram, paroxetine, fluoxetine, duloxetine) and four antipsychotics (first ziprasidone followed by aripiprazole, olanzapine, risperidone). A signal was also described for oxybate sodium and metoclopramide. For antidepressants, a negative association was found between ROR values and NET (norepinephrine transporter) but not SERT (serotonin transporter) pKi values, suggesting this ADR is more closely linked to norepinephrine than serotonin reuptake inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Selective Serotonin Reuptake InhibitorsBruxismAdultHumansPharmacovigilanceAntidepressive AgentsWorld Health Organization

Stichwörter der Autor:innen

adverse drug reactionsantidepressantsantipsychoticsbruxismpharmacovigilance

Substanzen

Selective Serotonin Reuptake InhibitorsAntidepressive Agents

Autor:innen und Institutionen

  • Emeritus Professor of Medical and Clinical Pharmacology, Toulouse, France.

ORCID-Profile: Jean-Louis Montastruc

Zitieren

APA

Montastruc, J. L. (2023). Drugs and bruxism: A study in the World Health Organization's pharmacovigilance database. British Journal of Clinical Pharmacology, 89(12), 3765-3768. https://doi.org/10.1111/bcp.15884

Vancouver

Montastruc JL. Drugs and bruxism: A study in the World Health Organization's pharmacovigilance database. British Journal of Clinical Pharmacology. 2023;89(12):3765-3768. doi:10.1111/bcp.15884

BibTeX
@article{Montastruc2023,
  author = {Montastruc, Jean-Louis},
  title = {Drugs and bruxism: A study in the World Health Organization's pharmacovigilance database},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  volume = {89},
  number = {12},
  pages = {3765--3768},
  doi = {10.1111/bcp.15884}
}
Kostenlos starten →